Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

Published:2017-02-13 Issue:6 Volume:101 Page:721-724
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Xu XS¹,Yan X¹,Puchalski T²,Lonial S³,Lokhorst HM⁴,Voorhees PM⁵,Plesner T⁶,Liu K¹,Khan I¹,Jansson R²,Ahmadi T²,Ruixo JJ Perez⁷,Zhou H²,Clemens PL²

Affiliation:

1. Janssen Research & Development, LLC; Raritan New Jersey USA

2. Janssen Research & Development, LLC; Spring House Pennsylvania USA

3. Department of Hematology and Medical Oncology, Winship Cancer Institute; Emory University; Atlanta Georgia USA

4. VU University Medical Center; Amsterdam The Netherlands

5. Division of Hematology/Oncology, Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill; Chapel Hill North Carolina USA

6. Vejle Hospital and University of Southern Denmark; Vejle Denmark

7. Janssen Research & Development; Beerse Belgium

Funder

Janssen Research & Development, LLC

Janssen Global Services, LLC

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference7 articles.

1. Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU;McKeage;Drugs Ther. Perspect.,2016

2. Targeting CD38 with daratumumab monotherapy in multiple myeloma;Lokhorst;N. Engl. J. Med.,2015

3. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitor (PI) and immunomodulatory drug (IMiD) treatment;Clemens;Clin. Lymphoma Myeloma Leuk.,2015

4. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial;Lonial;Lancet,2016

5. Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis;Yan;Blood,2015

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation;Cytotherapy;2024-05

2. Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development;Clinical Pharmacology & Therapeutics;2024-01-10

3. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13

4. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction;Journal of Oncology Pharmacy Practice;2023-11-21

5. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14